Company: TXG
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001770787-25-000013
Chunk: 2

Company: 10x Genomics, Inc.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 8
Chunk 2
---
We have served as the Company’s auditor since 2015.

San Jose, California

February 12, 2025

78

10x Genomics, Inc.

Consolidated Balance Sheets

(In thousands, except share and per share data)

December 31,20242023AssetsCurrent assets:Cash and cash equivalents$344,067 $359,284 Marketable securities49,335 29,411 Accounts receivable, net87,862 114,832 Inventory83,107 73,706 Prepaid expenses and other current assets20,016 18,789 Total current assets584,387 596,022 Property and equipment, net252,648 279,571 Operating lease right-of-use assets57,290 65,361 Goodwill4,511 4,511 Intangible assets, net15,671 16,616 Other noncurrent assets4,129 3,062 Total assets$918,636 $965,143 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$12,909 $15,738 Accrued compensation and related benefits33,615 30,105 Accrued expenses and other current liabilities41,165 56,648 Deferred revenue20,658 13,150 Operating lease liabilities9,286 11,521 Total current liabilities117,633 127,162 Operating lease liabilities, noncurrent73,327 83,849 Deferred revenue, noncurrent12,513 8,814 Other noncurrent liabilities5,029 4,275 Total liabilities208,502 224,100 Commitments and contingencies (Note 7)Stockholders' equity:Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2024 and 2023— — Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 122,291,837 (Class A 108,235,004, Class B 14,056,833) and 119,095,362 (Class A 105,038,529, Class B 14,056,833) shares issued and outstanding as of December 31, 2024 and 2023, respectively